Tisotumab vedotin-tftv
Tisotumab vedotin-tftv is a tissue factor (TF)-directed antibody and microtubule inhibitor conjugate. The drug is designed to bind to the cervical cancer cells expressing TF and then deliver the chemotherapy, the microtubule inhibitor, payload into the cells. It belongs to the class of antibody-drug conjugates or ADCs.
Tisotumab vedotin-tftv is indicated for the treatment of patients with recurrent or metastatic cervical cancer.
Provider Resources
